ClinicalTrials.gg
CompletedNCT01657019Updated Jun 9, 2021Results posted

Open Label Extension in Adults With Binge Eating Disorder (BED)

A Phase 3 interventional study of Lisdexamfetamine dimesylate in Binge Eating Disorder, sponsored by Shire. Completed at 89 sites in 3 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
604
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Enrollment
2nd of 112
604 · median 67
Started
2012
with 2 others
Phase 3
15 of 122
2 open now
Registered
30th of 122
by date
Lead sponsor
5 of 122
Shire

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 2nd largest by enrollment of the 112 interventional ones that give a count, is one of 3 that started in 2012, is one of 15 in phase 3, and was the 30th registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults

03

Conditions studied

  • Binge Eating Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completion of an antecedent SPD489 BED Double-blind Study
  2. Subject meets the following Fourth Edition - Text Revision (DSM-IV-TR) criteria for a diagnosis of BED
  3. Subject has a (BMI) of > or =18 and \< or =45

Exclusion criteria

Exclusion criteria:

  1. Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.
  2. Subject is considered a suicide risk or risk to harm others
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
604 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine dimesylate

    Drug: Lisdexamfetamine dimesylate

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) as a Measure of Safety

    Time frame: 52 weeks

  2. Number of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS)

    Suicidality was assessed by using the C-SSRS, a semi-structured interview designed to capture the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview and rating for the C-SSRS was completed by a clinician who had been successfully trained by the sponsor or designee. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answers to the first 2 ideation questions were "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "no," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.

    Time frame: 53 weeks

Secondary outcomes

  1. Percentage of Participants With an Improved Response on The Clinical Global Impressions of Improvement (CGI-I) Scale

    The CGI rating scales permitted the global evaluation of a participant's condition severity and improvement over time. The CGI-I was performed to rate the improvement of a participant's condition on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) and included a 'not assessed' option. The responses were dichotomized into 2 categories (improved or not improved). Improved included very much improved and much improved; not improved included minimally improved, no change, minimally worse, much worse, and very much worse. Not assessed and missing values were excluded from the percentage calculation.

    Time frame: Weeks 1, 4, 24, and 52, and end of treatment (either Visit 16 [Week 52] or Early Termination)

  2. Change From Baseline in The Global Score for The Eating Disorder Examination Questionnaire (EDE-Q)

    The EDE-Q is a 28-item questionnaire measuring eating pathology and is derived directly from the Eating Disorder Examination Interview. The EDE-Q focuses on the past 28 days to assess the main behavioral (eating and purging) and attitudinal features of eating disorders. The 28 items are rated by the participant on a 7-point scale (ranging from 0 to 6), with higher scores indicating increased pathology. The EDE-Q includes 4 subscales: Restraint, Eating Concern, Weight Concern, and Shape Concern. The global score is the average of all 28 items, with a range of 0 to 6. A negative value indicates a favorable result. The values presented are the mean change from baseline.

    Time frame: Baseline, Weeks 4, 24, and 52, and end of treatment (either Visit 16 [Week 52] or Early Termination)

  3. Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Mobility

    The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the mobility questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

    Time frame: End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)

  4. Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care

    The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the self care questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

    Time frame: End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)

  5. Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities

    The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the usual activities questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

    Time frame: End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)

  6. Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort

    The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the pain/discomfort questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

    Time frame: End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)

  7. Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety or Depression

    The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the anxiety/depression questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

    Time frame: End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)

07

Results

Posted Dec 15, 2015

Participant flow

This was an open-label extension study to evaluate the long-term safety of SPD489 in adults aged 18-55 years with binge eating disorder (BED) who completed 1 of 3 antecedent studies, all of which tested SPD489 for BED (SPD489-208, SPD489-343, or SPD489-344).

Participant flow — Overall Study
MilestoneAll Participants
Started604
Completed369
Not completed235
Withdrew: Withdrawal by subject65
Withdrew: Adverse event55
Withdrew: Lost to follow-up48
Withdrew: Protocol violation6
Withdrew: Lack of efficacy3
Withdrew: Other58

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) as a Measure of Safety
Time frame:
52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) as a Measure of Safety
percentage of participantsAll Participants
Any TEAE84.5
Serious TEAEs2.8
PrimaryNumber of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS)

Suicidality was assessed by using the C-SSRS, a semi-structured interview designed to capture the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview and rating for the C-SSRS was completed by a clinician who had been successfully trained by the sponsor or designee. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answers to the first 2 ideation questions were "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "no," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.

Time frame:
53 weeks
Reported as:
Number · participants
Number of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS)
participantsAll Participants
Suicidal behavior0
Active suicidal ideation2
Non-suicidal self-injurious behavior3
SecondaryPercentage of Participants With an Improved Response on The Clinical Global Impressions of Improvement (CGI-I) Scale

The CGI rating scales permitted the global evaluation of a participant's condition severity and improvement over time. The CGI-I was performed to rate the improvement of a participant's condition on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) and included a 'not assessed' option. The responses were dichotomized into 2 categories (improved or not improved). Improved included very much improved and much improved; not improved included minimally improved, no change, minimally worse, much worse, and very much worse. Not assessed and missing values were excluded from the percentage calculation.

Time frame:
Weeks 1, 4, 24, and 52, and end of treatment (either Visit 16 [Week 52] or Early Termination)
Reported as:
Number · percentage of participants
Percentage of Participants With an Improved Response on The Clinical Global Impressions of Improvement (CGI-I) Scale
percentage of participantsAll Participants
Visit 1 (Week 1), n=58953.7 (49.6 to 57.7)
Visit 4 (Week 4), n=57288.5 (85.8 to 91.1)
Visit 9 (Week 24), n=46692.7 (90.3 to 95.1)
Visit 16 (Week 52), n=36995.4 (93.2 to 97.5)
End of Treatment, n=59789.9 (87.5 to 92.3)
SecondaryChange From Baseline in The Global Score for The Eating Disorder Examination Questionnaire (EDE-Q)

The EDE-Q is a 28-item questionnaire measuring eating pathology and is derived directly from the Eating Disorder Examination Interview. The EDE-Q focuses on the past 28 days to assess the main behavioral (eating and purging) and attitudinal features of eating disorders. The 28 items are rated by the participant on a 7-point scale (ranging from 0 to 6), with higher scores indicating increased pathology. The EDE-Q includes 4 subscales: Restraint, Eating Concern, Weight Concern, and Shape Concern. The global score is the average of all 28 items, with a range of 0 to 6. A negative value indicates a favorable result. The values presented are the mean change from baseline.

Time frame:
Baseline, Weeks 4, 24, and 52, and end of treatment (either Visit 16 [Week 52] or Early Termination)
Reported as:
Mean · units on a scale
Change From Baseline in The Global Score for The Eating Disorder Examination Questionnaire (EDE-Q)
units on a scaleAll Participants
Visit 4 (Week 4), n=483-1.66 ± 1.156
Visit 9 (Week 24), n=391-1.95 ± 1.271
Visit 16 (Week 52), n=314-1.95 ± 1.261
End of Treatment, n=503-1.90 ± 1.284
SecondaryPercentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Mobility

The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the mobility questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

Time frame:
End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)
Reported as:
Number · percentage of participants at ET
Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Mobility
percentage of participants at ETAll Participants
I have no problems in walking about91.2
I have slight problems in walking about6.8
I have moderate problems in walking about1.4
I have severe problems in walking about0.4
I am unable to walk about0.2
SecondaryPercentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care

The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the self care questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

Time frame:
End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)
Reported as:
Number · percentage of participants at ET
Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care
percentage of participants at ETAll Participants
I have no problems washing or dressing myself97.1
I have slight problems washing or dressing myself1.8
Moderate problems washing or dressing myself0.7
I have severe problems washing or dressing myself0.2
I am unable to wash or dress myself0.2
SecondaryPercentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities

The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the usual activities questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

Time frame:
End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)
Reported as:
Number · percentage of participants at ET
Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities
percentage of participants at ETAll Participants
I have no problems doing my usual activities88.5
I have slight problems doing my usual activities8.3
Moderate problems doing my usual activities2.2
I have severe problems doing my usual activities0.9
I am unable to do my usual activities0.2
SecondaryPercentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort

The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the pain/discomfort questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

Time frame:
End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)
Reported as:
Number · percentage of participants at ET
Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort
percentage of participants at ETAll Participants
I have no pain or discomfort71.2
I have slight pain or discomfort20.9
I have moderate pain or discomfort7.0
I have severe pain or discomfort0.9
I have extreme pain or discomfort0
SecondaryPercentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety or Depression

The EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health. The percentages of participants with various responses to the anxiety/depression questionnaire are reported. Percentages are based on all participants in the Full Analysis Set with a valid result at the given visit.

Time frame:
End of Treatment (ET; either Visit 16 [Week 52] or Early Termination)
Reported as:
Number · percentage of participants at ET
Percentage of Participants With a Response to The EuroQoL Group 5 Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety or Depression
percentage of participants at ETAll Participants
I am not anxious or depressed75.9
I am slightly anxious or depressed18.7
I am moderately anxious or depressed4.5
I am severely anxious or depressed0.9
I am extremely anxious or depressed0

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants—17/599 (2.8%)447/599 (74.6%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventAll Participants
Cholecystitis acuteHepatobiliary disorders2/599
Hip fractureInjury, poisoning and procedural complications1/599
Acute coronary syndromeCardiac disorders1/599
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/599
PneumoniaInfections and infestations1/599
Intestinal perforationGastrointestinal disorders1/599
AsthmaRespiratory, thoracic and mediastinal disorders1/599
CholelithiasisHepatobiliary disorders1/599
Liver function test abnormalInvestigations1/599
Road traffic accidentInjury, poisoning and procedural complications1/599
Most frequent other events
Showing 10 of 32
Most frequent other events
EventAll Participants
Dry mouthGastrointestinal disorders163/599
HeadacheNervous system disorders79/599
InsomniaPsychiatric disorders74/599
Upper respiratory tract infectionInfections and infestations68/599
NasopharyngitisInfections and infestations53/599
ConstipationGastrointestinal disorders41/599
NauseaGastrointestinal disorders41/599
IrritabilityGeneral disorders36/599
Decreased appetiteMetabolism and nutrition disorders36/599
SinusitisInfections and infestations35/599

Baseline characteristics

Safety Analysis Set, defined as all participants who took at least 1 dose of investigational product and who had at least 1 post-Visit 0 safety assessment in the study.

Age, Continuous
Age, Continuous(years)All Participants
Mean39.0 ± 9.98
Age, Customized
Age, Customized(Participants)All Participants
< 40 years301
>/= 40 years298
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female521
Male78
08

Study locations

89 sites
  • Birmingham Research Group
    Birmingham, Alabama 35216, United States
  • Radiant Research
    Tucson, Arizona 85710, United States
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72211, United States
  • Southwestern Research, Inc.
    Beverly Hills, California 90210, United States
  • TRIMED Clinical Trials
    Corona, California 92880, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • Scripps Clinical Research Services
    La Jolla, California 92037, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Pacific Research Partners, LLC
    Oakland, California 94612, United States
  • Excell Research, Inc
    Oceanside, California 92056, United States
  • PCSD - Feighner Research
    San Diego, California 92108, United States
  • Western Affiliated Research Institute, Inc
    Denver, Colorado 80209, United States
  • Radiant Research, Inc
    Denver, Colorado 80239, United States
  • Florida Clinical Research
    Bradenton, Florida 34201, United States
  • Gulfcoast Clinical Research
    Fort Myers, Florida 33912, United States
  • Clinical Neuroscience Solutions, Inc
    Jacksonville, Florida 32216, United States
  • Fidelity Clinical Research, Inc
    Lauderhill, Florida 33319, United States
  • Compass Research, LLC
    Leesburg, Florida 34748, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • Scientific Clinical Research, Inc
    North Miami, Florida 33161, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida 32806, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Atlanta Institute of Medicine and Research
    Atlanta, Georgia 30328, United States
  • Neurotrials Research, Inc
    Atlanta, Georgia 30342, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Baber Research Group
    Naperville, Illinois 60563, United States
  • American Medical Research, Inc
    Oak Brook, Illinois 60523, United States
  • Goldpoint Clinical Research, LLC
    Indianapolis, Indiana 46260, United States
  • Deaconess Health Center
    Newburgh, Indiana 47630, United States
  • Clinical Trials Technology, Inc
    Prairie Village, Kansas 66206, United States
  • Cypress Medical Research Center, LLC
    Wichita, Kansas 67226, United States
  • Louisana Research Associates, Inc
    New Orleans, Louisiana 70114, United States
  • McLean Hospital
    Belmont, Massachusetts 02478, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Activmed Practices & Research
    Methuen, Massachusetts 01844, United States
  • Adams Clinical Trials, LLC
    Watertown, Massachusetts 02472, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • University of Minnesota
    Minneapolis, Minnesota 55454, United States
  • St. Charles Psychiatric Associates-Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Robert Lynne Horne, MD
    Las Vegas, Nevada 89102, United States
  • Center for Psychiatry & Behavioral Medicine, Inc
    Las Vegas, Nevada 89128, United States
  • Global Medical Institues, LLC
    Princeton, New Jersey 08540, United States
  • Pacific Institute for Research & Evaluation
    Albuquerque, New Mexico 87102, United States
  • Brooklyn Medical Institute
    Brooklyn, New York 11214, United States
  • Comprehensive Clinical Development
    Jamaica, New York 11432, United States
  • Bioscience Research LLC
    Mount Kisco, New York 10549, United States
  • CNS Clinica
    New York, New York 10023, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Radiant Research, Inc
    Akron, Ohio 44311, United States
  • Patient Priority Clinical Sites
    Cincinnati, Ohio 45215, United States
  • Community Research
    Cincinnati, Ohio 45227, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Lindner Center of Hope
    Mason, Ohio 45040, United States
  • North Star Medical Research, LLC
    Middleburg Heights, Ohio 44130, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Oregon Psychiatric Partners, Llp
    Eugene, Oregon 97401, United States
  • Sunstone Medical Research, LLC
    Medford, Oregon 97504, United States
  • Oregon Center for Clinical Research, Inc
    Portland, Oregon 97210, United States
  • Oregon Center for Clinical Investigations, Inc
    Salem, Oregon 97301, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • The Clinical Trial Center, LLC.
    Jenkintown, Pennsylvania 19046, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Clinical Trials Research Services, LLC
    Pittsburgh, Pennsylvania 15206, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Radiant Research, Inc
    Anderson, South Carolina 29621, United States
  • Radiant Research, Inc
    Greer, South Carolina 29650, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Clinical Neuroscience Solutions, Inc (CNS Healthcare)
    Memphis, Tennessee 38119, United States
  • Clinical Research Associates, Inc
    Nashville, Tennessee 37203, United States
  • Futuresearch Clinical Trials
    Austin, Texas 78731, United States
  • Futuresearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Texas Center for Drug Development, Inc
    Houston, Texas 77081, United States
  • Psychiatric Medical Associates
    Plano, Texas 75093, United States
  • Radiant Research, Inc
    San Antonio, Texas 78229, United States
  • Grayline Clinical Drug Trials
    Wichita Falls, Texas 76309, United States
  • Radiant Research, Inc
    Murray, Utah 84123, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • Neuropsychiatric Associates
    Woodstock, Vermont 05091, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
  • Neuroscience, Inc
    Herndon, Virginia 20170, United States
  • Northwest Clinical Research
    Bellevue, Washington 98007, United States
  • Summit Research Network (Seattle) LLC
    Seattle, Washington 98104, United States
  • Dean Foundation
    Middleton, Wisconsin 53562, United States
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • Ernovis GmbH
    Berlin, 10629, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 1069, Germany
  • Klinische Forschung Hannover-Mitte
    Hannover, 30159, Germany
  • Hospital Infanta Leonor
    Madrid, 28031, Spain
09

References and documents

Publications

  • Gasior M, Hudson J, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder. J Clin Psychopharmacol. 2017 Jun;37(3):315-322. doi: 10.1097/JCP.0000000000000702. PubMed 28383364 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2012 to primary completion in Oct 2014, 26 months.

Results were first posted in Dec 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2012
First posted
Aug 3, 2012
StartActual
Aug 21, 2012
Primary completionActual
Oct 21, 2014
CompletionActual
Oct 21, 2014
Results first posted
Dec 15, 2015
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01657019
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Aug 3, 2012
Start date
Aug 21, 2012
Primary completion
Oct 21, 2014
Completion
Oct 21, 2014
Results posted
Dec 15, 2015
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion